Tr1 cells: An unrecognized obstacle to Immunotherapy by Robert Schreiber – Cancer Research Institute
Cancer Research Institute shared on LinkedIn:
“Aiming to understand and to address the limitations of immunotherapy, CRI Scientific Advisory Council Associate Director Dr. Robert Schreiber of Washington University School of Medicine in St. Louis ‘found that the immune system can be its own worst enemy in the fight against cancer.’ In a new study published in Springer Nature Group‘s Nature, Dr. Schreiber observed that a subset of immune cells that normally puts the brakes on the immune system to prevent it from attacking the body’s healthy cells inadvertently also dampens cancer immunotherapy.
‘Tr1 cells were found to be a heretofore unrecognized obstacle to immunotherapy’s effectiveness against cancer,’ describes senior author Dr. Schreiber. ‘By removing or circumventing that barrier in mice, we successfully reenergized the immune system’s cancer-fighting cells and uncovered an opportunity to expand the benefits of immunotherapy for more cancer patients.'”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023